Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
The annual general meeting in PEPTONIC medical AB (the "Company") was held today, 26 June 2025, at Eversheds Sutherland Advokatbyrå's premises at Sveavägen 20 in Stockholm. The following main resolutions were passed with the required majority at the meeting.
Adoption of the income statement and balance sheet
The meeting adopted the income statement and balance sheet as included in the annual report for 2024.
Allocation of results
The meeting resolved that the Company's results shall be allocated in accordance with the board's proposal in the annual report. No dividend will be paid for the financial year 2024.
Discharge from liability
Each of the board members and the CEO were discharged from liability for the 2024 administration in accordance with the auditor's recommendation.
Determination of the number of board members and deputy board members
The meeting resolved that the board of directors shall consist of four (4) members without deputies.
Remuneration to the board of directors and auditor
The meeting resolved that remuneration of SEK 200,000 shall be paid to each of the ordinary members and SEK 250,000 to the chairman of the board. Since the Company is currently subject to a corporate reorganization process, it was resolved, in accordance with the board's proposal, that no remuneration shall be paid for the period until the decision the corporate reorganization process has become final.
It was further resolved that the auditor's fee shall be paid in accordance with approved invoices in accordance with customary billing standards.
Election of board of directors and auditor
It was resolved to re-elect Daniel Rudeklint, Anders Blom, Jacob Eriksson and Tarek Schoeb as board members. Anders Blom was re-elected as chairman of the board. The company's auditor KPMG AB was re-elected as auditor with Dan Beitner as auditor-in-charge.
Amendment of the articles of association
It was resolved to amend the articles of association as set out below.
| Previous wording | New wording |
| § 1 Company name The company's name is PEPTONIC medical AB (publ). | § 1 Company name The company's name is Peptonic Medical AB (publ). |
| § 2 Registered office The board shall have its registered office in Uppsala. | § 2 Registered office The board of directors shall have its registered office in Stockholm. |
| § 5 Number of shares The number of shares shall be not less than 5,700,000,000 and not more than 22,800,000,000. | § 5 Number of shares The number of shares shall be not less than 8,739,130,000 and not more than 34,956,520,000. |
| § 8 Notice and venue for general meetings Notice of an annual general meeting or notice of an extraordinary general meeting where the question of amending the articles of association will be dealt with, shall be given no earlier than six and no later than four weeks before the meeting. Notice of any other extraordinary general meeting shall be given not earlier than six weeks and not later than two weeks before the meeting. Notice of a general meeting shall be published in the Swedish Official Gazette and on the company's website. The fact that notice has been given shall be announced in Dagens Industri. Together with the notice, a proposed agenda for the general meeting shall be attached, clearly stating the matters to be addressed by the meeting. The items shall be numbered and state their main content. General meetings shall be held in Uppsala, Stockholm or Växjö municipality. | § 8 Notice and venue for general meetings Notice of an annual general meeting or notice of an extraordinary general meeting where the question of amending the articles of association will be dealt with, shall be given no earlier than six and no later than four weeks before the meeting. Notice of any other extraordinary general meeting shall be given not earlier than six weeks and not later than two weeks before the meeting. Notice of a general meeting shall be published in the Swedish Official Gazette and on the company's website. The fact that notice has been given shall be announced in Dagens industri. Together with the notice, a proposed agenda for the general meeting shall be attached, clearly stating the matters to be addressed by the meeting. The items shall be numbered and state their main content. General meetings shall be held in Uppsala or Stockholm municipality. |
Authorisation for the board of directors to resolve on new issues of shares, warrants and/or convertibles
It was resolved to authorise the board of directors, during the period until the next annual General Meeting, to decide on the issue of new shares, warrants and/or convertible bonds. If the Board of Directors exercises the authorisation, it may also be done with deviation from the shareholders' preferential rights and/or with provisions on non-cash payment or set-off.
Issues pursuant to this authorization shall be made on market terms. The board of directors shall have the right to determine the other terms and conditions for issues pursuant to this authorization and who shall be entitled to subscribe for the securities issued. The reason why the board of directors shall be able to decide on issues in deviation from the shareholders' preferential rights and/or with provisions regarding non-cash consideration or set-off is to enable the Company to raise capital for the Company, implement strategically motivated collaborations or company acquisitions, and facilitate the implementation of issues for the purpose of strengthening the Company's financial position.
For further information, please contact:
Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About PEPTONIC medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The company is headquartered in Stockholm, Sweden, and operate the subsidiaries Peptonic medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.